Live
- First Impressions and Unboxing of the MacBook Pro M4: A Powerhouse for Professionals and Creators
- China Gears Up for Potential Trade War Amid Trump’s Tariff Threats
- Small Farmers Gain Less by Selling to Supermarkets: Study Reveals
- Why Despite the Controversy, America Is Anticipating the Mike Tyson vs. Jake Paul Fight
- Sanju Samson and Tilak Varma Shine: Record-Breaking Feats in 4th T20I Against South Africa
- India Urges $1.3 Trillion Annual Climate Support for Developing Nations
- Bad air: 106 shuttle buses, 60 extra Metro trips planned to make Delhiites give up cars
- WHO reports declining monkeypox cases in Congo
- CM Attends Kotideepotsavam on Kartika Purnima
- PKL Season 11: Raiding trio of Devank, Ayan, Sandeep help Patna Pirates rout Bengal Warriorz
DNA-based Zika vaccine found effective in early human trial
An experimental DNA-based vaccine has demonstrated both safety and the ability to elicit an immune response against Zika virus in humans, according to new research.
New York: An experimental DNA-based vaccine has demonstrated both safety and the ability to elicit an immune response against Zika virus in humans, according to new research.
The Phase-1 clinical trial showed that humans who received up to three doses of the vaccine candidate produced an immune response against Zika with minimal adverse effects.
The findings open the door to further clinical trials for this vaccine candidate. The GLS-5700 vaccine is a synthetic DNA vaccine that contains the instructions for the host to mount an immune response against a specific Zika virus antigen.
"With these new results, we are one step closer to hopefully finding a way to prevent infection, which can cause serious birth defects and developmental delays in babies born to women who are infected with Zika," said the study's lead author, Pablo Tebas, Professor at University of Pennsylvania in the US.
In 2015 and 2016, Zika virus spread rapidly through Brazil, the Caribbean, and even into the southern US. However, a vaccine to prevent infection has remained elusive. For this study, the researchers enrolled 40 participants in the safety trial between August and September of 2016.
